Discuva

Discuva is a biotechnology firm focused on the research and development of novel therapeutics, particularly in combating infectious diseases through innovative solutions that enhance treatment efficacy. Discuva, established in 2007, is based in Cambridge, UK. The company specializes in the development of new therapeutic approaches for infectious diseases. The founder, Nawaz Khan, has a background in developing innovative medical solutions.

In December 2011, Discuva raised GBP 2. 00 million from New Wave Ventures, valuing the company at GBP 25. 40 million post-money. The firm has secured a total of GBP 2.

00 million in funding, with the most recent funding round being on 2011-12-02. Discuva focuses on the research and development of innovative therapeutic solutions aimed at addressing infectious diseases, utilizing advanced drug discovery techniques to identify and develop new compounds. Their approach involves a comprehensive understanding of microbial resistance and targets, leading to the creation of effective treatments for patients suffering from various infections. In the most recent financial year, Discuva reported revenue of GBP 0.

00. The company's EBITDA for 2023 stood at GBP -1,924,290. 50, reflecting the ongoing investment in research and development activities without immediate revenue generation. Discuva plans to leverage its recent funding of GBP 2.

00 million to enhance its research capabilities and expedite the development of its therapeutic candidates. The company aims to expand its market presence into Europe and North America by 2025, focusing on establishing partnerships with healthcare providers to facilitate the distribution of its products. With ongoing clinical trials and a commitment to addressing global health challenges, Discuva is poised to advance its therapeutic solutions into new markets.